Astellas scores a pair of trial wins for menopausal hot flash med, raising the pitch of looming Bayer standoff
Astellas took a flier on women’s health when it bought out Ogeda and nonhormonal menopause candidate fezolinetant in early 2017 and then doubled down during a major restructuring just over a year later. Now, an early peek at late-stage studies bode well for Astellas’ chances — and it could be teeing up a fight with Bayer.
In a pair of Phase III studies dubbed SKYLIGHT 1 and 2, two doses of Astellas’ fezolinetant topped placebo in reducing the frequency and severity of hot flashes in menopausal women at one- and three-month check ins, according to topline data unveiled Friday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
